{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:43:02Z","timestamp":1794246182387,"version":"4.9.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Limited studies have assessed the long-term benefit\/risk of gene therapy for Leber hereditary optic neuropathy (LHON).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To determine the safety and efficacy of lenadogene nolparvovec in patients with LHON due to the\n                      <jats:italic>MT-ND4<\/jats:italic>\n                      gene variant for up to 5 years after administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      The RESCUE and REVERSE Long-Term Follow-up Study (RESTORE), conducted from 2018 to 2022, is the 5-year follow-up study of the 2 phase 3 clinical studies RESCUE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss Up to 6 Months From Onset in LHON Due to the\n                      <jats:italic>MT-ND4<\/jats:italic>\n                      Mutation) and REVERSE (Efficacy Study of Lenadogene Nolparvovec for the Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the\n                      <jats:italic>MT-ND4<\/jats:italic>\n                      Mutation). At the end of each study, ie, 2 years after gene therapy administration, patients were offered enrollment in the RESTORE trial, a multinational, multicenter, prospective study, for an additional 3 years of follow-up. Patients with LHON due to the\n                      <jats:italic>MT-ND4<\/jats:italic>\n                      gene variant received lenadogene nolparvovec in 1 eye and a sham injection in the other eye.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Lenadogene nolparvovec was administered as a single intravitreal injection in the RESCUE\/REVERSE studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Measures included best-corrected visual acuity (BCVA), quality of life using the National Eye Institute visual functioning questionnaire 25 (NEI VFQ-25), and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 76 patients who received gene therapy in the RESCUE (n\u2009=\u200939) and REVERSE (n\u2009=\u200937) studies, 72 (94.7%) completed these studies; 62 patients (81.6%) participated in the RESTORE trial, and 55 patients (72.4%) completed the 5-year follow-up. Participants were mostly male (49 [79.0%]) with a mean (SD) age of 35.9 (15.3) years at treatment. At baseline, the mean (SD) BCVA was 1.5 (0.5) logMAR (20\/600 Snellen) in eyes to be treated with lenadogene nolparvovec and 1.4 (0.5) logMAR (20\/500) in sham eyes. At the end of the RESCUE\/REVERSE trials, ie, 2 years after treatment, eyes treated with lenadogene nolparvovec and eyes treated with sham reached a mean BCVA value of 1.4 (0.6) logMAR (20\/500). The mean (SD) change from baseline to year 2 was \u22120.05 (0.6) logMAR (+1 line) and 0.01 (0.6) logMAR (\u22120 line) in gene therapy\u2013treated and sham eyes, respectively (difference, \u22120.03; 95% CI, \u22120.16 to 0.09;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.60). Five years after treatment, the bilateral improvement from nadir was similar to that observed at 2 years, with a mean (SD) change in BCVA of \u22120.4 (0.5) logMAR (more than +4 lines) for eyes treated with lenadogene nolparvovec and \u22120.4 (0.4) logMAR (+4 lines) for eyes treated with sham (difference, \u22120.05; 95% CI, \u22120.15 to 0.04;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.27). An improvement of at least \u22120.3 logMAR (+3 lines) from the nadir in at least 1 eye was observed in 66.1% of participants (41 of 62). Between 2 and 5 years, intraocular inflammation was noted in 4 participants with 8 events in eyes treated with lenadogene nolparvovec and 1 event in an eye treated with sham.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>\n                      In this analysis of the RESTORE trial, follow-up of patients with LHON due to the\n                      <jats:italic>MT-ND4<\/jats:italic>\n                      gene variant unilaterally treated with lenadogene nolparvovec demonstrated a sustained bilateral improvement in BCVA and a good safety profile up to 5 years after treatment. This evidence of persistent benefit over time is promising for the use of gene therapy in these patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03406104\">NCT03406104<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.5375","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:02:09Z","timestamp":1734606129000},"page":"99","source":"Crossref","is-referenced-by-count":34,"title":["Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy"],"prefix":"10.1001","volume":"143","author":[{"given":"Patrick","family":"Yu-Wai-Man","sequence":"first","affiliation":[{"name":"Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom"},{"name":"Cambridge Eye Unit, Addenbrooke\u2019s Hospital, Cambridge University Hospitals, Cambridge, United Kingdom"},{"name":"Moorfields Eye Hospital, London, United Kingdom"},{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Department of Neurology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Biousse","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Department of Neurology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Carelli","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy"},{"name":"Unit of Neurology, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Moster","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wills Eye Hospital and Thomas Jefferson University, Philadelphia, Pennsylvania"},{"name":"Department of Ophthalmology, Wills Eye Hospital and Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vignal-Clermont","sequence":"additional","affiliation":[{"name":"Department of Neuro Ophthalmology and Emergencies, Rothschild Foundation Hospital, Paris, France"},{"name":"Centre Hospitalier National D\u2019Ophtalmologie des Quinze Vingts, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klopstock","sequence":"additional","affiliation":[{"name":"Friedrich-Baur-Institute, Department of Neurology, University Hospital, Ludwig-Maximilians University, Munich, Germany"},{"name":"German Center for Neurodegenerative Diseases, Munich, Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo A.","family":"Sadun","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, UCLA School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Sergott","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wills Eye Hospital and Thomas Jefferson University, Philadelphia, Pennsylvania"},{"name":"Department of Ophthalmology, Wills Eye Hospital and Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Hage","sequence":"additional","affiliation":[{"name":"Centre Hospitalier National D\u2019Ophtalmologie des Quinze Vingts, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Degli Esposti","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital, London, United Kingdom"},{"name":"UCL Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"La Morgia","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy"},{"name":"Unit of Neurology, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"},{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Priglinger","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital, Ludwig-Maximilians-University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustum","family":"Karanja","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Ottawa Eye, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Taiel","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[{"name":"Centre Hospitalier National D\u2019Ophtalmologie des Quinze Vingts, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM, CNRS, Institut de la Vision, Paris, France"},{"name":"Fondation Ophtalmologique A. de Rothschild, Paris, France"},{"name":"Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LHON Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Barboni","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Carbonelli","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Di Vito","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Amore","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Contin","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mohamed","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Silvestri","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Baker Hubbard","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Hendrick","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dattilo","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Peragallo","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hawy","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindreth","family":"DuBois","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gibbs","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alcides","family":"Fernandes Filho","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannah","family":"Dobbs","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Aung","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Acheson","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Boston","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eleftheriadou","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gemenetzi","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Leitch-Devlin","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Tucker","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neringa","family":"Jurkute","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Burale","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A.","family":"DeBusk","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Haller","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Massini","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"SantaMaria","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Tollis","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Girmens","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Plaine","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahiba","family":"Khemliche","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia B.","family":"Catarino","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Priglinger","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Rudolph","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Thurau","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"von Livonius","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muth","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Wolf","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Al-Tamami","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Pressler","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosima","family":"Schertler","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neuenhahn","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Heilweil","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Tsui","sequence":"additional","affiliation":[{"name":"for the LHON Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi240080r1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.preteyeres.2010.11.002","article-title":"Mitochondrial optic neuropathies\u2014disease mechanisms and therapeutic strategies.","volume":"30","author":"Yu-Wai-Man","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"eoi240080r2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/WNO.0000000000001564","article-title":"The impact of Leber hereditary optic neuropathy on the quality of life of patients and their relatives: a qualitative study.","volume":"42","author":"Chen","year":"2022","journal-title":"J Neuroophthalmol"},{"issue":"2","key":"eoi240080r3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40259-021-00468-9","article-title":"Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study.","volume":"35","author":"Vignal-Clermont","year":"2021","journal-title":"BioDrugs"},{"issue":"5","key":"eoi240080r4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 Months of disease onset.","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"issue":"573","key":"eoi240080r5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"eoi240080r6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/brain\/awac421","article-title":"Randomized trial of bilateral gene therapy injection for m.11778G&gt;A MT-ND4 Leber optic neuropathy.","volume":"146","author":"Newman","year":"2023","journal-title":"Brain"},{"issue":"3","key":"eoi240080r7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/WNO.0000000000001367","article-title":"Long-term follow-up after unilateral intravitreal gene therapy for Leber hereditary optic neuropathy: the RESTORE study.","volume":"41","author":"Biousse","year":"2021","journal-title":"J Neuroophthalmol"},{"issue":"7","key":"eoi240080r8","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire.","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"eoi240080r9","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1167\/iovs.08-3225","article-title":"Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from 2 phase 3 clinical trials.","volume":"50","author":"Su\u00f1er","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"eoi240080r10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40123-022-00611-x","article-title":"Indirect comparison of lenadogene nolparvovec gene therapy vs natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G&gt;A MT-ND4 mutation.","volume":"12","author":"Carelli","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"eoi240080r11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.662838","article-title":"Intravitreal gene therapy vs natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G&gt;A ND4 mutation: systematic review and indirect comparison.","volume":"12","author":"Newman","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"eoi240080r12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12883-022-02787-y","article-title":"Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report.","volume":"22","author":"Newman","year":"2022","journal-title":"BMC Neurol"},{"issue":"4","key":"eoi240080r13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","article-title":"International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy.","volume":"37","author":"Carelli","year":"2017","journal-title":"J Neuroophthalmol"},{"issue":"10","key":"eoi240080r14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3390\/life13102000","article-title":"Leber hereditary optic neuropathy (LHON): clinical experience and outcomes after long-term idebenone treatment.","volume":"13","author":"Balta","year":"2023","journal-title":"Life (Basel)"},{"issue":"6","key":"eoi240080r15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00401-016-1625-2","article-title":"A neurodegenerative perspective on mitochondrial optic neuropathies.","volume":"132","author":"Yu-Wai-Man","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"4","key":"eoi240080r16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/WNO.0000000000001045","article-title":"Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G&gt;A (MTND4) mitochondrial DNA mutation.","volume":"40","author":"Newman","year":"2020","journal-title":"J Neuroophthalmol"},{"key":"eoi240080r17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.omtm.2021.09.013","article-title":"Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates.","volume":"23","author":"Calkins","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"eoi240080r18","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2023.03.035","article-title":"Ocular stress enhances contralateral transfer of lenadogene nolparvovec gene therapy through astrocyte networks.","volume":"31","author":"McGrady","year":"2023","journal-title":"Mol Ther"},{"issue":"11","key":"eoi240080r20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results.","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi240080r21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ophtha.2020.02.023","article-title":"Seven-year follow-up of gene therapy for Leber hereditary optic neuropathy.","volume":"127","author":"Yuan","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi240080r22","doi-asserted-by":"publisher","first-page":"21587","DOI":"10.1038\/srep21587","article-title":"Efficacy and safety of rAAV2-ND4 treatment for Leber hereditary optic neuropathy.","volume":"6","author":"Wan","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"eoi240080r23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/WNO.0000000000001023","article-title":"Real-world clinical experience with idebenone in the treatment of Leber hereditary optic neuropathy.","volume":"40","author":"Catarino","year":"2020","journal-title":"J Neuroophthalmol"},{"issue":"Pt 9","key":"eoi240080r24","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber hereditary optic neuropathy.","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain"},{"issue":"9","key":"eoi240080r26","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases.","volume":"58","author":"Csaky","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"eoi240080r27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ajo.2022.11.026","article-title":"Safety of lenadogene nolparvovec gene therapy over 5 years in 189 patients with Leber hereditary optic neuropathy.","volume":"249","author":"Vignal-Clermont","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"eoi240080r19","author":"Sadun","year":"2023"},{"key":"eoi240080r25","unstructured":"European Medicines Agency. Raxone. Accessed December 15, 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/raxone"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2828184\/jamaophthalmology_yuwaiman_2024_oi_240080_1739913511.04053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:02:18Z","timestamp":1740049338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2828184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.5375","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}